Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

drug reimbursement

- PMLiVE

Outcomes shape the new European payer networks

In the new commercial reality of cost-constrained healthcare environments the payer is everywhere

China flag thumb

China’s bribery probe goes national

Expands investigation that already affects GSK, Sanofi, Lilly, AZ, Lundbeck, Novo and UCB

China flag thumb

Sanofi drawn into Chinese corruption probe

Joins GSK, UCB, AZ , Lilly, Novo and Lundbeck as companies under scrutiny

Roche's Perjeta pertuzumab

Roche’s breast cancer drug too expensive for NHS use

But pharma company says UK Government dithering on Perjeta patient access scheme

China flag thumb

Sanofi and Lilly also visited by Chinese authorities

Follows GSK bribery allegations

- PMLiVE

AbbVie sales jump on strong Humira gains

Extra indications help boost performance of treatment for autoimmune disorders

- PMLiVE

Modern values in healthcare

Understanding the new concepts and processes of value will be the first steps towards adapting to a new healthcare environment

- PMLiVE

GSK replaces China head as bribery probe rolls on

Herve Gisserot takes over from Mark Reilly

- PMLiVE

Witty says Chinese bribery probe will impact GSK

CEO says company’s performance in China will be affected

- PMLiVE

FDA panel fails to back new use for AbbVie’s Humira

Votes 12 to 1 against new use in spondyloarthritis

China flag thumb

AstraZeneca and UCB drawn into Chinese investigations

Follows country’s clampdown on GSK bribery

- PMLiVE

GSK concedes execs may have broken Chinese law

President of international operations suggests senior execs were involved in bribery scandal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links